Table 2.
Participants’ characteristics
| C-Mill therapy (n = 16) |
FALLS program (n = 17) | p value | |
|---|---|---|---|
| Gender (female/male) | 9/7 | 5/12 | 0.13c |
| Age at intake (years) | 52 ± 13 | 59 ± 10 | 0.13a |
| Height (cm) | 171 ± 10 | 175 ± 7 | 0.40a |
| Body mass (kg) | 76 ± 13 | 80 ± 14 | 0.18a |
| Time since stroke at intake (months, median) | 46 (6–372) | 20 (13–110) | 0.05c |
| Side of lesion (left/right) | 9/7 | 8/9 | 0.66c |
| Functional Ambulation Category (FAC) at intake (1–5, median) | 5 (4–5) | 5 (4–5) | 0.99c |
| Berg Balance Scale (BBS) (0–56, median) | 55 (39–56) | 53 (46–56) | 0.58c |
| Mini-Mental State Examination MMSE (0–30, median) | 29 (26–30) | 28 (22–30) | 0.63c |
| Assistive device (none/(k)evo/walking cane) | 6/4/6 | 10/3/4 | 0.22c |
| Level of activity (1–5 days a week at least 30 min moderate active) | 1 (0–5) | 2 (0–5) | 0.31c |
| Falls past year (n, %) | 8, 50% | 13, 76% | 0.12b |
| Fear of falling (1 (no fear of falling)–10 (extreme fear of falling)) | 5 (1–9) | 3 (1–10) | 0.31c |
| Living situation (independently/independently with help) | 3/13 | 6/11 | 0.42c |
| Comorbidities (n, %) | 9, 57% | 10, 59% | 0.58b |
p values were obtained using aIndependent t-test, bFisher’s exact test, or cMann-Whitney U test. Tendencies towards significant differences are presented in italic (0.05 < p < 0.075)